For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
0
references
 Top references
cited by
40
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that neutralises membrane and soluble B-cell activating factor (BAFF).

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Ann. Rheum. Dis.
          Title: Annals of the rheumatic diseases
          Publisher: BMJ
          ISSN (Electronic): 1468-2060
          ISSN (Print): 0003-4967
          Publication date (Electronic): Feb 2016
          Volume: 75
          Issue: 2
          Affiliations
          [1 ] Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
          [2 ] Department of Medicine, Karolinska Institute, Stockholm, Sweden.
          [3 ] New York University School of Medicine, New York, New York, USA.
          [4 ] Division of Rheumatology and Allergy-Clinical Immunology, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York, USA.
          [5 ] Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
          [6 ] Eli Lilly and Company, Indianapolis, Indiana, USA.
          [7 ] Medicine/Rheumatology and Clin Immunology, Charité Universitätsmedizin, Berlin, Germany.
          Article
          Publisher Item ID: annrheumdis-2015-207654
          DOI: 10.1136/annrheumdis-2015-207654
          PubMed ID: 26293163
          SO-VID: e9d0ecd1-cb7b-44d3-9115-d04a0b70d2fc
          History

          Keywords: Autoimmune Diseases,B cells,Disease Activity,Systemic Lupus Erythematosus
          Data availability:
          Keywords: Autoimmune Diseases, B cells, Disease Activity, Systemic Lupus Erythematosus

          Comments

          Comment on this article